Sigyn Therapeutics™ Appoints Accomplished CFO Jeremy Ferrell as Chief Financial Officer

Sigyn Therapeutics, Inc.

SAN DIEGO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on treating conditions associated with pathogens that induce sepsis, today announced the appointment of Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.

As Chief Financial Officer, Mr. Ferrell will have overall responsibility for operational finance, budgeting and financial reporting, as well as managing Sigyn’s relationships and interactions with the investment community.

Mr. Ferrell has over 25 years of finance and operations leadership experience, with expertise in venture capital; Mergers and Acquisitions; due diligence; initial public offerings; strategic alliance negotiation; and financial planning and reporting. He was most recently CFO at Miku, Inc, a privately held consumer hardware and telehealth company, where he successfully managed a seed funding round and led Miku’s transition from its parent company to an independent company. Previously, he founded Fractional CFO Services, where he served as CFO for various life science and technology companies, including Singular Genomics, Inc., Aspen Neuroscience, Inc., and Hyduro, Inc. Prior to that Mr. Ferrell was a corporate controller for ecoATM, Inc., which was acquired by Outerwall, Inc. in 2013. Earlier in his career, Mr. Ferrell practiced as a certified public accountant. Mr. Ferrell earned his Bachelor of Science in Accounting from Liberty University and his Masters of Business Administration in International Finance from the Thunderbird School of Global Management.

“We are very pleased to have recruited a leader of Jeremy’s caliber to this key position,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “His comprehensive and demonstrable track record of accomplishments in helping technology companies successfully navigate change and growth will be a major asset to Sigyn as we move Sigyn TherapyTM into the clinic and continue to list our securities on an exchange. major.”

Mr. Ferrell commented: “I am delighted to join the Sigyn team at such an upsetting time. Sigyn Therapy is a differentiated blood purification technology that offers broad, well-defined market opportunities and the potential to address significant unmet global health needs. I look forward to helping the Company execute its strategic plan and create value for its shareholders. »

About Sigyn Therapeutics™

Sigyn Therapeutics is a medical technology company focused on treating conditions associated with pathogens that precipitate sepsis, the leading cause of hospital death worldwide. Sigyn Therapy™ is a multifunctional blood purification technology that extracts pathogenic sources of life-threatening inflammation in concert with broad-spectrum removal of inflammatory mediators from the bloodstream.

To learn more, visit www.SigynTherapeutics.com

Caution Regarding Forward-Looking Statements

The information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may”, “believe”, “anticipate”, “expect”, “intend”, “plan”, “project”, “will”, “projections”, ” estimate”, “potentially” or similar expressions constitute forward-looking statements. These forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based on Sigyn’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to these differences may include, but are not limited to, the Company’s ability to clinically advance Sigyn Therapy in the human studies required for marketing authorization, the Company’s ability to manufacture Sigyn Therapy, the Company’s ability to raise capital resources and other potential risks. The above list of risks and uncertainties is illustrative but not exhaustive. Other factors that could cause results to differ materially from those anticipated in the forward-looking statements can be found under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. , and in the other documents filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as required by law, the Company does not intend, nor undertakes any obligation, to update this information to reflect future events or circumstances.

contacts:

Stephen Kilmer
Sigyn Therapeutics, Inc.
Investor Relations
(646) 274-3580
[email protected]

Media contacts:

Russo Partners, LLC

david schull
(212) 845-4271
[email protected]

Nic Johnson
(212) 845-4242
[email protected]

Comments are closed.